InsidersTradesSigma
Follow the Impedimed Limited share price and the full insider trade history of the company, a listed issuer based in Australia. Shares trade on the AU market, under the supervision of ASX. Operating in the Health Care sector, Impedimed Limited has published 6 public disclosures. Market capitalisation: €22m. The latest transaction was filed on 3 June 2026 (Purchase). Among the most active insiders: FORM 603. The full history is accessible without an account.
6
Insider Decl.
n/a
Thresholds
n/a
5 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Impedimed Limited Strong Buy (bullish), based on 4 analysts. Average price target: A$0.02.
2Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,321 of 29,064 companies
27.8
score / 100
Value8
Quality47
FCF yld-22%
Earn yld-33%
EV/EBITDA·
ROE-162%
Gross mgn86%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 June 2026
关于 Impedimed Limited
Impedimed Limited 是一家医疗技术公司，专注于开发淋巴疾病的诊断和管理解决方案。该公司在XASX市场上市。